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Cost-Effectiveness of Olanzapine as a First-Line Treatment: 
A Response to Comment
To the Editor––We appreciate the interest from Dr.
Basu in our recent manuscript and are pleased with the
favorable comments about the study design, its robust
analysis, and important results. We welcome the
opportunity to further discuss our ﬁndings and address
Dr. Basu’s comments about the economic evaluations
of the fail-ﬁrst design. Dr. Basu astutely observed that
a small proportion of the patients randomized to treat-
ment with conventional antipsychotics (about one-
third of this group) were successfully treated with con-
ventional antipsychotics, thus incurred lower medica-
tion costs than patients who were successfully treated
with olanzapine. Dr. Basu extrapolated from our data,
and hypothesized that if a subset of patients who
would be successfully treated by both medications
were treated with conventional antipsychotics, there
would then be an average cost saving of $367 per
patient per year. While under a set of assumptions
these calculations are correct, these calculations ignore
the ﬁndings that two-thirds of the patients who would
be started on conventional antipsychotics, would not
be successfully treated, thus incur higher relapse-
related costs.
By virtue of the randomized nature of our 1-year
study, the total cost for olanzapine therapy estimates
the average annual cost per patient if all patients in the
population had been treated with olanzapine. Simi-
larly, our estimates for the fail-ﬁrst on conventional
antipsychotics produce estimates that had a fail-ﬁrst
algorithm been used for all patients. Thus, these esti-
mates––which show no difference in total costs––are a
valid approach to answering the question of the cost of
a fail-ﬁrst policy. Showing the beneﬁt of a fail-ﬁrst by
demonstrating medication cost advantages for a small
subset of the patients is not sufﬁcient.
It is vital to recognize that for patients with schiz-
ophrenia, treatment failure is not without adverse clin-
ical, social, legal, and economic ramiﬁcations,
primarily because of relapse and hospitalizations [1,2].
The total costs of treatment failure should therefore be
incorporated into any decision-making process about
antipsychotic medication choice.
That said, Dr. Basu’s observations raise an impor-
tant point. If one were to be able to identify, with high
accuracy, which patients would and would not
respond to conventional antipsychotics before treat-
ment––then some form of cost savings by using con-
ventional antipsychotics in this subset may be realized.
Nevertheless, no such accurate model has been devel-
oped to date, and providers are unable to accurately
and reliably identify in advance who will successfully
respond to what medication.
Interestingly, Dr. Basu opted to multiply the hypoth-
esized $367 cost savings by 5, to reﬂect a potential 5-
year cost saving of $1731 per patient. We ﬁnd this
extrapolation speculative. Not only is it based on
extrapolating the hypothesized 1-year cost savings, it
also assumes that patients will continue treatment with
the conventional antipsychotic for 5 years. This
assumption is inconsistent with the dynamic nature of
pharmacotherapy for schizophrenia [3]. The CATIE
Schizophrenia trial [4] has shown, for example,
patients with schizophrenia stay on their initial rand-
omized antipsychotic medications for an average of
6 months, with differences in median treatment dura-
tion among the studied antipsychotics (olanzapine
9.2 months, perphenazine––a conventional antipsy-
chotic–−5.6 months, risperidone 4.8 months, quetiap-
ine 4.6 months, and ziprasidone 3.5 months).
Therefore, ﬁndings suggest that Dr. Basu’s hypothe-
sized savings––while theoretically plausible––are not
likely to materialize because the stated assumptions are
incongruent with real-world medication utilization
practices.––Sandra L. Tunis, PhD, Independent
Research Consultant, Douglas E. Faries, PhD, Allen W.
Nyhuis, MS, Bruce J. Kinon, MD, and Haya Ascher-
Svanum, PhD, US Medical Division, Eli Lilly and Com-
pany, Indianapolis, IN, USA; and Ralph Aquila, MD,
The Center for Reintegration, New York, NY, USA.
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